Search

Your search keyword '"Campion, Loïc"' showing total 178 results
Start Over Author "Campion, Loïc" Search Limiters Available in Library Collection
178 results on '"Campion, Loïc"'

1. TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial

Author

Féray, Cyrille, Campion, Loic, Mathurin, Philippe, Archambreaud, Isabelle, Mirabel, Xavier, Bronowicki, Jean Pierre, Rio, Emmanuel, Perret, Christophe, Mineur, Laurent, Oberti, Frédéric, Touchefeu, Yann, Gournay, Jérôme, Regnault, Hélène, Edeline, Julien, Rode, Agnès, Hillion, Patrick, Blanc, Jean Frédéric, Khac, Eric Nguyen, Azoulay, Daniel, Luciani, Alain, Preglisasco, Athena Galetto, Faurel-Paul, Elodie, Auble, Hélène, Mornex, Françoise, and Merle, Philippe

Published
2023
Full Text
View/download PDF

3. The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability

Author

Derrien, Jennifer, Guérin-Charbonnel, Catherine, Gaborit, Victor, Campion, Loïc, Devic, Magali, Douillard, Elise, Roi, Nathalie, Avet-Loiseau, Hervé, Decaux, Olivier, Facon, Thierry, Mallm, Jan-Philipp, Eils, Roland, Munshi, Nikhil C., Moreau, Philippe, Herrmann, Carl, Magrangeas, Florence, and Minvielle, Stéphane

Published
2021
Full Text
View/download PDF

4. Exploring the impact of dexamethasone on gene regulation in myeloma cells

Author

Bessonneau-Gaborit, Victor, primary, Cruard, Jonathan, additional, Guerin-Charbonnel, Catherine, additional, Derrien, Jennifer, additional, Alberge, Jean-Baptiste, additional, Douillard, Elise, additional, Devic, Magali, additional, Deshayes, Sophie, additional, Campion, Loïc, additional, Westermann, Frank, additional, Moreau, Phillipe, additional, Herrmann, Carl, additional, Bourdon, Jérémie, additional, Magrangeas, Florence, additional, and Minvielle, Stéphane, additional

Published
2023
Full Text
View/download PDF

6. Abstract OT1-09-01: Axillary surgery de-escalation after neoadjuvant chemotherapy in breast cancer patients with initially involved node: the GANEA 3 trial

Author

Renaudeau, Céline, primary, Gimbergues, Pierre, additional, Guillot, Eugénie, additional, Chauvet, Marie-Pierre, additional, Gutowski, Marian, additional, Jouve, Eva, additional, Rauch, Philippe, additional, Cohen, Monique, additional, Faure, Christelle, additional, Padeano, Marie-Martine, additional, Ceccato, Vivien, additional, Uzan, Catherine, additional, Bats, Anne-Sophie, additional, Charitansky, Hélène, additional, Dupré, Pierre-François, additional, Reynard, Augustin, additional, Alran, Séverine, additional, Bendavid-Athias, Cécile, additional, Campion, Loïc, additional, Doutriaux, Isabelle, additional, and Classe, Jean-Marc, additional

Published
2023
Full Text
View/download PDF

7. Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults

Author

Le Bourgeois, Amandine, Peterlin, Pierre, Guillaume, Thierry, Delaunay, Jacques, Duquesne, Alix, Le Gouill, Steven, Moreau, Philippe, Mohty, Mohamad, Campion, Loïc, and Chevallier, Patrice

Published
2016
Full Text
View/download PDF

9. Prospective Multicentric Assessment of 68Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET

Author

Lugat, Alexandre, primary, Frampas, Éric, additional, Touchefeu, Yann, additional, Mirallié, Éric, additional, Bras, Maëlle Le, additional, Senellart, Hélène, additional, Rauscher, Aurore, additional, Fleury, Vincent, additional, Campion, Loïc, additional, Rohmer, Vincent, additional, Couturier, Olivier-François, additional, Lebtahi, Rachida, additional, Rouzet, François, additional, Ruszniewski, Philippe, additional, Kraeber-Bodéré, Françoise, additional, Bourgeois, Mickaël, additional, and Ansquer, Catherine, additional

Published
2023
Full Text
View/download PDF

10. Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database

Author

Bini, Marta, primary, Quesada, Stanislas, additional, Meeus, Pierre, additional, Rodrigues, Manuel, additional, Leblanc, Eric, additional, Floquet, Anne, additional, Pautier, Patricia, additional, Marchal, Frédéric, additional, Provansal, Magali, additional, Campion, Loïc, additional, Causeret, Sylvain, additional, Gourgou, Sophie, additional, Ray-Coquard, Isabelle, additional, Classe, Jean-Marc, additional, Pomel, Christophe, additional, De La Motte Rouge, Thibault, additional, Barranger, Emmanuel, additional, Savoye, Aude Marie, additional, Guillemet, Cécile, additional, Gladieff, Laurence, additional, Demarchi, Martin, additional, Rouzier, Roman, additional, Courtinard, C, additional, Romeo, Clémence, additional, and Joly, Florence, additional

Published
2022
Full Text
View/download PDF

11. Prospective Multicentric Assessment of 68 Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET.

Author

Lugat, Alexandre, Frampas, Éric, Touchefeu, Yann, Mirallié, Éric, Bras, Maëlle Le, Senellart, Hélène, Rauscher, Aurore, Fleury, Vincent, Campion, Loïc, Rohmer, Vincent, Couturier, Olivier-François, Lebtahi, Rachida, Rouzet, François, Ruszniewski, Philippe, Kraeber-Bodéré, Françoise, Bourgeois, Mickaël, and Ansquer, Catherine

Subjects
PANCREATIC tumors, RESEARCH, DISEASE progression, PERITONEAL cancer, POSITRON emission tomography computed tomography, RADIOISOTOPES, MAGNETIC resonance imaging, CANCER relapse, GASTROINTESTINAL tumors, GALLIUM isotopes, CANCER patients, NEUROENDOCRINE tumors, SINGLE-photon emission computed tomography, BONE metastasis, SOMATOSTATIN, DESCRIPTIVE statistics, RESEARCH funding, COMPUTED tomography, SENSITIVITY & specificity (Statistics), LONGITUDINAL method, NEUROTRANSMITTER receptors
Abstract

Simple Summary: Determining the most sensitive imaging technique to evaluate neuroendocrine tumors spread may have an impact on therapeutic management. The aim of this multicentric study was to prospectively assess 68Ga-DOTANOC PET/CT sensitivity compared to the combination of multiphasic CT, somatostatin receptor scintigraphy and MRI to evaluate whether this imaging modality results in therapeutic modifications. We confirm in a homogenous population of 105 grade 1 or 2 gastroenteropancreatic neuroendocrine tumors the higher sensitivity of 68Ga-DOTANOC PET/CT in per-patient and per-region analysis, as well as in the detection of primary tumor and small lesions such as peritoneal carcinomatosis and bone lesions leading to an impact on therapeutic management of almost half of the patients. The aim of this multicentric study was to prospectively compare 68Ga-DOTANOC PET/CT versus somatostatin receptor scintigraphy (SRS) with SPECT/CT, combined with multiphasic CT scan and MRI in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NET). Patients with histologically proven grade 1 or 2 GEP-NET with suspicion of recurrence or progression, or with typical aspects of GEP-NET on morphological imaging, were explored with conventional imaging (CI): SRS with SPECT/CT, multiphasic CT scan and/or liver MRI followed by 68Ga-DOTANOC PET/CT. The gold standard was based on histology and imaging follow-up. The data of 105 patients (45 woman and 60 men; median age) were analyzed. 68Ga-DOTANOC PET/CT sensitivity was significantly higher than CI sensitivity in per-patient (98.9% vs. 88.6%, p = 0.016) and per-region (97.6% vs. 75.6%, p < 0.001) analyses, in the detection of the primary (97.9% vs. 78.7%; p = 0.016), peritoneal carcinomatosis (95% vs. 30%, p < 0.001), and bone metastases (100% vs. 33.3%, p = 0.041). 68Ga-DOTANOC PET/CT had an impact on the therapeutic management of 41.9% (44/105) patients compared to decisions based on CI explorations. Our data confirm the superiority of 68Ga-DOTANOC PET/CT over CI in the detection of peritoneal carcinomatosis and bone metastasis, as well as its strong therapeutic impact on the management of patients with grade 1-2 GEP-NETs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Additional file 3 of The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability

Author

Derrien, Jennifer, Guérin-Charbonnel, Catherine, Gaborit, Victor, Campion, Loïc, Devic, Magali, Douillard, Elise, Roi, Nathalie, Avet-Loiseau, Hervé, Decaux, Olivier, Facon, Thierry, Mallm, Jan-Philipp, Eils, Roland, Munshi, Nikhil C., Moreau, Philippe, Herrmann, Carl, Magrangeas, Florence, and Minvielle, Stéphane

Abstract

Additional file 3 Figures S1–S30. Supplementary figures.

Published
2021
Full Text
View/download PDF

14. Additional file 3 of DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma

Author

Jean-Baptiste Alberge, Magrangeas, Florence, Wagner, Mirko, Denié, Soline, Guérin-Charbonnel, Catherine, Campion, Loïc, Attal, Michel, Avet-Loiseau, Hervé, Carell, Thomas, Moreau, Philippe, Minvielle, Stéphane, and Sérandour, Aurélien A.

Abstract

Additional file 3. Methods: This file describes normal plasma cells purification, myeloma cells purification, 5mC and 5hmC dosage by mass spectrometry, bioinformatics methods and statistical analysis.

Published
2020
Full Text
View/download PDF

15. Additional file 2 of DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma

Author

Jean-Baptiste Alberge, Magrangeas, Florence, Wagner, Mirko, Denié, Soline, Guérin-Charbonnel, Catherine, Campion, Loïc, Attal, Michel, Avet-Loiseau, Hervé, Carell, Thomas, Moreau, Philippe, Minvielle, Stéphane, and Sérandour, Aurélien A.

Abstract

Additional file 2. Table S1: Patients characteristics, survival and mass spectrometry quantification of 5hmC and 5mC. Table S2: Scoring of 1816 5hmC-enriched domains across NDMM samples. Table S3: Motif analysis of core regulatory circuitries. Table S4: Scoring of groups-specific 5hmC-enriched domains. Table S5: Differential 5hmC-enriched domains between at diagnosis and relapse (DiffBind analysis).

Published
2020
Full Text
View/download PDF

16. Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in HER2-negative Breast Cancer

Author

Rousseau, Caroline, Goldenberg, David, Colombié, Mathilde, Sébille, Jean-Charles, Meingan, Philippe, Ferrer, Ludovic, Baumgartner, Pierre, Cerato, Evelyne, Masson, Damien, Campone, Mario, Rauscher, Aurore, Fleury, Vincent, Labbé, Catherine, Faivre-Chauvet, Alain, Fresnel, Jean-Sebastien, Toquet, Claire, Barbet, Jacques, Sharkey, Robert, Campion, Loïc, Kraeber-Bodéré, Françoise, Bernardo, Elizabeth, Nucléaire pour la Santé - - ARRONAXPLUS2011 - ANR-11-EQPX-0004 - EQPX - VALID, Radiopharmaceutiques Innovants en Oncologie et Neurologie - - IRON2011 - ANR-11-LABX-0018 - LABX - VALID, Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), IBC Pharmaceuticals Inc [Morris Plains, NJ, USA], Immunomedics Inc. [Morris Plains, NJ, USA], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Service de Médecine Nucléaire [Nantes], Hôpital Laennec, Service de Radiologie [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Physique [Nantes] (GIP Arronax), ARRONAX - (GIP) Groupement d'Intérêt Public [Saint-Herblain] (Institut de Recherche Public), PHU 11 Pharmacie [CHU Nantes] (Pharmacie Centrale), Délégation à la Recherche Clinique et à l'Enovation [Nantes] ((DRCI)), Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Biologie des Cancers [ICO, Nantes], UNICANCER-UNICANCER, Institut d'oncologie de l'Ouest [CHU Nantes], Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Département de Pathologie [CHU Nantes], Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), Plateforme de Biométrie [CHU Nantes] (Hôtel Dieu), Supported in part by grants from the University Hospital of Nantes and Fondation Avenir in 2010, the French National Agency for Research, called 'Investissements d’Avenir' IRON Labex ANR-11-LABX-0018-01 and ArronaxPlus Equipex ANR-11-EQPX-0004 and by a grant INCa-DGOS-Inserm_12558 (SIRIC ILIAD)., ANR-11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011), ANR-11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011), Oncologie nucléaire (CRCINA - Département NOHMAD - Equipe 13), Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Institut de cancérologie de l'Ouest - Nantes (ICO Nantes), CRLCC Paul Papin-CRLCC René Gauducheau, Institut de Cancérologie de l'Ouest, Integrative oncogenomics of multiple myeloma pathogenesis and progression (CRCINA - Département NOHMAD - Equipe 11), ANR-11-EQPX-0004/11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011), ANR-11-LABX-0018/11-LABX-0018,IRON,Radiopharmaceutiques Innovants en Oncologie et Neurologie(2011), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)

Subjects
bispecific antibody, Breast cancer, [SDV.CAN] Life Sciences [q-bio]/Cancer, PET/CT, gallium-68, Immuno-PET, pretargeting, [SDV.CAN]Life Sciences [q-bio]/Cancer, Oncology: Breast, Radioimmunoimaging
Abstract

International audience; Purpose: This prospective study evaluated the imaging performance of a novel immunological pretargeting positron-emission tomorgraphy (immuno-PET) method in patients with HER2-negative, carcinoembryonic antigen (CEA)-positive, metastatic breast cancer (BC), compared to computed tomography (CT), bone magnetic resonance imaging (MRI), and 18Fluorodeoxyglucose PET (FDG-PET). Patients and Methods: Twenty-three patients underwent whole-body immuno-PET after injection of 150 MBq 68Ga-IMP288, a histamine-succinyl-glycine peptide given following initial targeting of a trivalent anti-CEA, bispecific, anti-peptide antibody. The gold standards were histology and imaging follow-up. Tumor standard uptake values (SUVmax and SUVmean) were measured, and tumor burden analyzed using Total Tumor Volume (TTV) and Total Lesion Activity (TLA). Results: Total lesion sensitivity of immuno-PET and FDG-PET was 94.7% (1116/1178) and 89.6% (1056/1178), respectively. Immuno-PET had a somewhat higher sensitivity than CT and FDG-PET in lymph nodes (92.4% vs 69.7% and 89.4%, respectively) and liver metastases (97.3% vs 92.1% and 94.8%, respectively), whereas sensitivity was lower for lung metastases (48.3% vs 100% and 75.9%, respectively). Immuno-PET showed higher sensitivity than MRI and FDG-PET for bone lesions (95.8% vs 90.7% and 89.3%, respectively). In contrast to FDG-PET, immuno-PET disclosed brain metastases. Despite equivalent tumor SUVmax, SUVmean, and TTV, TLA was significantly higher with immuno-PET compared to FDG PET (P = 0.009). Conclusion: Immuno-PET using anti-CEA/anti-IMP288 bispecific antibody, followed by 68Ga-IMP288, is a potentially sensitive theranostic imaging method for HER2-negative, CEA-positive, metastatic BC patients, and warrants further research.

Published
2020

17. Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer

Author

Vaugier, Loïg, primary, Mirabel, Xavier, additional, Martel-Lafay, Isabelle, additional, Racadot, Séverine, additional, Carrie, Christian, additional, Vendrely, Véronique, additional, Mahé, Marc-André, additional, Senellart, Hélène, additional, Raoul, Jean-Luc, additional, Campion, Loïc, additional, and Rio, Emmanuel, additional

Published
2021
Full Text
View/download PDF

19. Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal Cancer

Author

Le Thiec, Maelle, primary, Testard, Aude, additional, Ferrer, Ludovic, additional, Guillerminet, Camille, additional, Morel, Olivier, additional, Maucherat, Bruno, additional, Rusu, Daniela, additional, Girault, Sylvie, additional, Lacombe, Marie, additional, Hamidou, Hadji, additional, Meyer, Véronique, additional, Rio, Emmanuel, additional, Hiret, Sandrine, additional, Kraeber-Bodéré, Françoise, additional, Campion, Loïc, additional, and Rousseau, Caroline, additional

Published
2020
Full Text
View/download PDF

20. Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?

Author

Goineau, Aurore, primary, Campion, Loïc, additional, Commer, Jean-Marie, additional, Vié, Brigitte, additional, Ghesquière, Agnès, additional, Béra, Guillaume, additional, Jaffres, Didier, additional, Magné, Nicolas, additional, Artignan, Xavier, additional, Chamois, Jérôme, additional, Bergerot, Philippe, additional, Créhange, Gilles, additional, Deniaud-Alexandre, Elisabeth, additional, Buthaud, Xavier, additional, Belkacémi, Yazid, additional, Doré, Mélanie, additional, De Decker, Laure, additional, and Supiot, Stéphane, additional

Published
2020
Full Text
View/download PDF

23. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT : impact on therapeutic decision-making and biomarker changes

Author

Rousseau, Caroline, Michaud, A., Barbaud, M., Morvant, C., Maucherat, B., Le Thiec, M., Rusu, D., Morel, A., Fleury, V., Colombie, M., Rauscher, A., Frindel, Mathieu, Baumgartner, P., Fleury, N., Campion, Loïc, Kraeber-Bodéré, Françoise, Bernardo, Elizabeth, Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de médecine nucléaire [Saint-Herblain], Centre René Gauducheau-Institut Régional du Cancer Nantes-Atlantique (IRCNA)-Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Unité de Pharmacie [ICO, Saint Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), Délégation à la recherche clinique [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Unité de Biométrie [ICO, Saint Herblain], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Centre René Gauducheau-Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), and UNICANCER-UNICANCER-Institut Régional du Cancer Nantes-Atlantique (IRCNA)

Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer, urologic and male genital diseases
Abstract

International audience; Aim/Introduction: The aim of this retrospective study was to investigate the impact of 68Ga-PSMA-11 PET/CT on current management of recurrence prostate cancer patients with negative PET/CT F-Choline. Materials and Methods: Eightynine patients with previously negative 18F-Choline (FCH) were enrolled (PSA from 0.28 to 24.6 ng/mL). PET images were recorded 1 hour after injection of 150 MBq of 68Ga-PSMA. Referring patient physician was asked about the care before and after PSMA PET imaging to determine the influence of PSMA results on therapeutic strategy. Six months after the end of treatment, a PSA assay was requested to evaluate therapeutic efficacy. Results: Sixty-nine among the 89 patients (77,5%) had a positive PSMA PET/CT. Detection rates were 85.6% and 89.4% for serum PSA levels lower than 2 ng/ml, and > 2 ng/ml, respectively. Three hundred and one lesions were detected: 235/301 in lymph nodes (78.1%), 38/301 as metastatic sites (bone, mostly on axial skeleton, or lung) (12.6%) and 28/301 in the prostate bed (9.3%). The majority of lesions were detected in lymph nodes: in particular with 71.5% pelvic nodes, on the other hand with 17.9% of para-aortic nodes and 10.6% with sus diaphragmatic location. For the para-aortic and subdiaphragmatic node locations, initial surgical management associated with pelvic salvage radiotherapy were the most common initial management which could explain the frequently supra-pelvic node recurrence. The median number of lesions per patient was 2 [ranging from 0 to 67]. No particularity of the PSA serum level, doubling time or PSA velocity at the time of PSMA PET-CT could explain why 68Ga-PSMA PET-CT was unable to detect any suspicious tumor lesions in 20 patients. Thanks to PSMA PET/CT, therapeutic management changed in 59/69 patients (84.9%). With a follow-up of 5.7 ± 1.8 months, 62/89 (69.6%) PSA assays after treatment guided by PSMA PET-CT were collected. For 43.5% (27/62) of patients, the serum PSA level was lower than 0.2 ng/mL and a total PSA decrease of over 50% in 35 (56.5%) patients was obtained. Conclusion: Performing a PSMA PET-CT when FCH PET-CT was negative allows the recurrence localization in more 80% of patients and this had a major clinical impact, as it resulted in treatment change in more than 80% of patients as well as a significant decrease in PSA levels in more than 55% of them. References: None.

Published
2019

24. Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy

Author

Oudoux, Aurore, Salaun, Pierre-Yves, Bournaud, Claire, Campion, Loïc, Ansquer, Catherine, Rousseau, Caroline, Bardet, Stéphane, Borson-Chazot, Françoise, Vuillez, Jean-Philippe, Murat, Arnaud, Mirallié, Eric, Barbet, Jacques, Goldenberg, David M., Chatal, Jean-François, and Kraeber-Bodéré, Françoise

Published
2007

26. Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study

Author

Bompas, Emmanuelle, Campion, Loïc, Italiano, Antoine, Le Cesne, Axel, Chevreau, Christine, Isambert, Nicolas, Toulmonde, Maud, Mir, Olivier, Ray-Coquard, Isabelle, Piperno-Neumann, Sophie, Saada-Bouzid, Esma, Rios, Maria, Kurtz, Jean-Emmanuel, Delcambre, Corinne, Dubray-Longeras, Pascale, Duffaud, Florence, Karanian, Marie, Le Loarer, Francois, Soulié, Patrick, Penel, Nicolas, Blay, Jean-Yves, CRLCC René Gauducheau, Institut Bergonié [Bordeaux], UNICANCER, Sarcome, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), Centre Léon Bérard [Lyon], Institut Curie [Paris], Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), Les Hôpitaux Universitaires de Strasbourg (HUS), Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), Assistance Publique - Hôpitaux de Marseille (APHM), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Service d'Oncologie Médicale, université de Bourgogne, LNC, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Université de Lille-UNICANCER, CHU Lille, Université de Lille, METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, Centre René Gauducheau, Institut Gustave Roussy [IGR], Département d'oncologie médicale [Centre Georges-François Leclerc], Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] [UNICANCER/ICL], Centre Régional de Lutte contre le Cancer François Baclesse [Caen] [UNICANCER/CRLC], Centre Jean Perrin [Clermont-Ferrand] [UNICANCER/CJP], CHU Marseille, Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO], Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS], and Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Adult, Male, Adolescent, genetic structures, [SDV]Life Sciences [q-bio], Review, Young Adult, pediatric, Adult cancer, rhabdomyosarcoma, Humans, Public Health Surveillance, Rhabdomyosarcoma, Embryonal, Aged, Retrospective Studies, Aged, 80 and over, musculoskeletal, neural, and ocular physiology, Middle Aged, Prognosis, musculoskeletal system, Combined Modality Therapy, Survival Analysis, eye diseases, Patient Outcome Assessment, [SDV] Life Sciences [q-bio], Treatment Outcome, Female, France, Cancer Prevention, human activities
Abstract

IF 3.202; International audience; Five-year overall survival (OS) of localized RMS exceeds 70% in children (

Published
2018

27. Early toxicity of a phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer (OLIGOPELVIS GETUG P07)

Author

Vaugier, Loig, Palpacuer, Clément, Rio, Emmanuel, Goineau, Aurore, Pasquier, David, Buthaud, Xavier, De Laroche, Guy, Beckendorf, Véronique, Sargos, Paul, Créhange, Gilles, Pommier, Pascal, Loos, Geneviève, Hasbini, Ali, Latorzeff, Igor, Silva, Marlon, Denis, Fabrice, Lagrange, Jean-Léon, Campion, Loïc, Supiot, Stephane, Bernardo, Elizabeth, Département de Radio-Oncologie [ICO, Nantes], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Département de Biostatistiques [ICO, Nantes], Service de la Radio-Oncologie [Angers], Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, Centre de Recherche en Informatique, Signal et Automatique de Lille - UMR 9189 (CRIStAL), Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Département de Radio-Oncologie [Nantes] (Centre Catherine de Sienne), Centre Catherine-de-Sienne [Nantes] (CCS), Département de Radio-Oncologie [Saint-Priest en Jarez] ( Institut de Cancérologie de la Loire), Institut de Cancérologie de la Loire [Saint-Priest en Jarez], Département de Radio-Oncologie [Vandoeuvre-lès-Nancy] (Centre Alexis Vautrin), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), Département de Radio-Oncologie [IB, Bordeaux] (Institut Bergonié), Institut Bergonié [Bordeaux], Service de radiothérapie [Centre Georges-François Leclerc], Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), Département de Radio-Oncologie [CLB, Lyon] (Centre Léon Bérard), Centre Léon Bérard [Lyon], Département de Radio-Oncologie [Clermont-Ferrand] (Centre Jean Perrin), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), Département de Radio-Oncologie [Brest] (Clinique Pasteur), Clinique Pasteur [Brest], Département de Radio-Oncologie [Toulouse] (Oncorad Clinique Pasteur), Oncorad Clinique Pasteur [Toulouse], Département de Radio-Oncologie [Baclesse, Caen], Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Jean Bernard [Institut Inter-régional de Cancérologie - Le Mans], Département de Radio-Oncologie [AP-HP Hôpital Henri Mondor], Hôpital Henri Mondor, Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Endothelium Radiobiology and Targeting (CRCINA-ÉQUIPE 14), This study was funded by Astellas., Université Lille Nord de France (COMUE)-UNICANCER, Centre Alexis Vautrin [Vandoeuvre-lès-Nancy], Département de Radio-Oncologie [Dijon] (CGFL Dijon), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)

Subjects
pelvic reirradiation, PSMA PET, [SDV.CAN] Life Sciences [q-bio]/Cancer, pelvis salvage irradiation, Fluorocholine PET, bowel toxicity, urinary toxicity, [SDV.CAN]Life Sciences [q-bio]/Cancer, IMRT, prostate cancer, IGRT
Abstract

International audience; PURPOSE:Limited pelvic nodal relapse of prostatic cancer is a paramount challenge for locoregional salvage treatments. Salvage whole pelvis radiotherapy as considered in the BLINDED trial, is an attractive option but with concerns about its toxicity. This article describes early toxicity with the technique.METHODS AND MATERIALS:BLINDED was a prospective multi-center phase II trial investigating high-dose salvage pelvic irradiation with an additional dose to the fluorocholine-based positron-emission-tomography (FCH-PET)-positive pelvic lymph nodes (PLN), combined with six-month androgen blockade. The prescribed dose was 54 Gy in 1.8 Gy fractions with up to 66 Gy in 2.2 Gy fractions to the pathological PLN. Early toxicity was defined until one year after radiotherapy. Patients quality of life was assessed using the EORTC questionnaires (QLQ-C30 and QLQ-PR25).RESULTS:Seventy-four patients were recruited in fifteen French radiation oncology departments between August 2014 and July 2016. Seven were excluded before treatment because of violation of the inclusion criteria. The intention-to-treat analysis therefore included sixty-seven patients. Half of them had received prior prostatic irradiation. Median age was 67.7 ± 6.5 years. Grade 2 acute urinary toxicity was observed in 9/67 patients (13.4%) and grade 2 one-year toxicity in 4/67 patients (6%). Three patients (4.4%) had grade 3 urinary toxicity. Grade 2 acute digestive toxicity was observed in 10/67 patients (14.9%) and grade 2 one-year toxicity in 4/67 patients (6%). Patients with prior prostate bed irradiation did not exhibit increased urinary or digestive toxicity. EORTC questionnaire scores at one year did not worsen significantly.CONCLUSIONS:The acute and one-year toxicity of the BLINDED protocol was satisfactory, even in patients with a past history of prostatic irradiation.

Published
2018

28. The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME)

Author

Pérol, David, primary, Robain, Mathieu, additional, Arveux, Patrick, additional, Mathoulin-Pélissier, Simone, additional, Chamorey, Emmanuel, additional, Asselain, Bernard, additional, Berchery, Delphine, additional, Gourgou, Sophie, additional, Breton, Mathias, additional, Delaine-Clisant, Stéphanie, additional, Mons, Muriel, additional, Diéras, Véronique, additional, Carton, Matthieu, additional, Guizard, Anne-Valérie, additional, Laborde, Lilian, additional, Laurent, Carine, additional, Loeb, Agnès, additional, Mouret-Reynier, Marie-Ange, additional, Parent, Damien, additional, Perrocheau, Geneviève, additional, Campion, Loïc, additional, Velten, Michel, additional, Cailliot, Christian, additional, Ezzalfani, Monia, additional, and Simon, Gaëtane, additional

Published
2019
Full Text
View/download PDF

29. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1

Author

Jézéquel Pascal, Campion Loïc, Charbonnel Catherine, Gouraud Wilfried, Gautier Fabien, Guillemin Yannis, Grau Morgan, Couriaud Cécile, Noël Bélinda, Campone Mario, Braun Frédérique, Barré Benjamin, Coqueret Olivier, Barillé-Nion Sophie, and Juin Philippe

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Anti-apoptotic signals induced downstream of HER2 are known to contribute to the resistance to current treatments of breast cancer cells that overexpress this member of the EGFR family. Whether or not some of these signals are also involved in tumor maintenance by counteracting constitutive death signals is much less understood. To address this, we investigated what role anti- and pro-apoptotic Bcl-2 family members, key regulators of cancer cell survival, might play in the viability of HER2 overexpressing breast cancer cells. Methods We used cell lines as an in vitro model of HER2-overexpressing cells in order to evaluate how anti-apoptotic Bcl-2, Bcl-xL and Mcl-1, and pro-apoptotic Puma and Bim impact on their survival, and to investigate how the constitutive expression of these proteins is regulated. Expression of the proteins of interest was confirmed using lysates from HER2-overexpressing tumors and through analysis of publicly available RNA expression data. Results We show that the depletion of Mcl-1 is sufficient to induce apoptosis in HER2-overexpressing breast cancer cells. This Mcl-1 dependence is due to Bim expression and it directly results from oncogenic signaling, as depletion of the oncoprotein c-Myc, which occupies regions of the Bim promoter as evaluated in ChIP assays, decreases Bim levels and mitigates Mcl-1 dependence. Consistently, a reduction of c-Myc expression by inhibition of mTORC1 activity abrogates occupancy of the Bim promoter by c-Myc, decreases Bim expression and promotes tolerance to Mcl-1 depletion. Western blot analysis confirms that naïve HER2-overexpressing tumors constitutively express detectable levels of Mcl-1 and Bim, while expression data hint on enrichment for Mcl-1 transcripts in these tumors. Conclusions This work establishes that, in HER2-overexpressing tumors, it is necessary, and maybe sufficient, to therapeutically impact on the Mcl-1/Bim balance for efficient induction of cancer cell death.

Published
2011
Full Text
View/download PDF

30. Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer

Author

Calais Gilles, Burtin Pascal, Carrie Christian, Salemkour Augustin, Vendrely Véronique, Chevelle Christian, Vié Brigitte, Martin Laurent, Leduc Bernard, Cellier Patrice, Campion Loïc, Boisdron-Celle Michèle, Morel Alain, Berger Virginie, and Gamelin Erick

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Considerable variation in intravenous 5-fluorouracil (5-FU) metabolism can occur due to the wide range of dihydropyrimidine dehydrogenase (DPD) enzyme activity, which can affect both tolerability and efficacy. The oral fluoropyrimidine tegafur-uracil (UFT) is an effective, well-tolerated and convenient alternative to intravenous 5-FU. We undertook this study in patients with locally advanced rectal cancer to evaluate the efficacy and tolerability of UFT with leucovorin (LV) and preoperative radiotherapy and to evaluate the utility and limitations of multicenter staging using pre- and post-chemoradiotherapy ultrasound. We also performed a validated pretherapy assessment of DPD activity and assessed its potential influence on the tolerability of UFT treatment. Methods This phase II study assessed preoperative UFT with LV and radiotherapy in 85 patients with locally advanced T3 rectal cancer. Patients with potentially resectable tumors received UFT (300 mg/m/2/day), LV (75 mg/day), and pelvic radiotherapy (1.8 Gy/day, 45 Gy total) 5 days/week for 5 weeks then surgery 4-6 weeks later. The primary endpoints included tumor downstaging and the pathologic complete response (pCR) rate. Results Most adverse events were mild to moderate in nature. Preoperative grade 3/4 adverse events included diarrhea (n = 18, 21%) and nausea/vomiting (n = 5, 6%). Two patients heterozygous for dihydropyrimidine dehydrogenase gene (DPYD) experienced early grade 4 neutropenia (variant IVS14+1G > A) and diarrhea (variant 2846A > T). Pretreatment ultrasound TNM staging was compared with postchemoradiotherapy pathology TN staging and a significant shift towards earlier TNM stages was observed (p < 0.001). The overall downstaging rate was 42% for primary tumors and 44% for lymph nodes. The pCR rate was 8%. The sensitivity and specificity of ultrasound for staging was poor. Anal sphincter function was preserved in 55 patients (65%). Overall and recurrence-free survival at 3 years was 86.1% and 66.7%, respectively. Adjuvant chemotherapy was administered to 36 node-positive patients (mean duration 118 days). Conclusion Preoperative chemoradiotherapy using UFT with LV plus radiotherapy was well tolerated and effective and represents a convenient alternative to 5-FU-based chemoradiotherapy for the treatment of resectable rectal cancer. Pretreatment detection of DPD deficiency should be performed to avoid severe adverse events.

Published
2011
Full Text
View/download PDF

32. Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients

Author

Goineau, Aurore, primary, Campion, Loïc, additional, d’Aillières, Bénédicte, additional, Vié, Brigitte, additional, Ghesquière, Agnès, additional, Béra, Guillaume, additional, Jaffres, Didier, additional, de Laroche, Guy, additional, Magné, Nicolas, additional, Artignan, Xavier, additional, Chamois, Jérôme, additional, Bergerot, Philippe, additional, Martin, Etienne, additional, Créhange, Gilles, additional, Deniaud-Alexandre, Elisabeth, additional, Buthaud, Xavier, additional, Belkacémi, Yazid, additional, Doré, Mélanie, additional, de Decker, Laure, additional, and Supiot, Stéphane, additional

Published
2018
Full Text
View/download PDF

33. Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using 18F-fluoromisonidazole PET/CT: a pilot study

Author

Supiot, Stéphane, primary, Rousseau, Caroline, additional, Dore, Mélanie, additional, Cheze-Le-Rest, Catherine, additional, Kandel-Aznar, Christine, additional, Potiron, Vincent, additional, Guerif, Stéphane, additional, Paris, François, additional, Ferrer, Ludovic, additional, Campion, Loïc, additional, Meingan, Philippe, additional, Delpon, Gregory, additional, Hatt, Mathieu, additional, and Visvikis, Dimitris, additional

Published
2018
Full Text
View/download PDF

34. A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Multiple Myeloma Patients

Author

Magrangeas, Florence, Kuiper, Rowan, Avet-Loiseau, Hervé, Gouraud, Wilfried, Guérin-Charbonnel, Catherine, Ferrer, Ludovic, Aussem, Alexandre, Elghazel, Haytham, Suhard, Jérôme, Der Sakissian, Henri, Attal, Michel, Munshi, Nikhil, Sonneveld, Pieter, Dumontet, Charles, Moreau, Philippe, Van Duin, Mark, Campion, Loïc, Minvielle, Stéphane, Centre de Recherche en Cancérologie / Nantes - Angers (CRCNA), Centre hospitalier universitaire de Nantes (CHU Nantes)-Faculté de Médecine d'Angers-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Centre National de la Recherche Scientifique (CNRS)-Hôpital Laennec-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôtel-Dieu de Nantes, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de cancérologie de l'Ouest - Nantes (ICO Nantes), CRLCC Paul Papin-CRLCC René Gauducheau, Data Mining and Machine Learning (DM2L), Laboratoire d'InfoRmatique en Image et Systèmes d'information (LIRIS), Université Lumière - Lyon 2 (UL2)-École Centrale de Lyon (ECL), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Lumière - Lyon 2 (UL2)-École Centrale de Lyon (ECL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA), Institut de Cancérologie de l'Ouest, Institut de Recherche en Communications et en Cybernétique de Nantes (IRCCyN), Mines Nantes (Mines Nantes)-École Centrale de Nantes (ECN)-Ecole Polytechnique de l'Université de Nantes (Polytech Nantes), Université de Nantes (UN)-Université de Nantes (UN)-PRES Université Nantes Angers Le Mans (UNAM)-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse], Lebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Harvard Medical School [Boston] (HMS), Boston Veterans Administration Healthcare System, West Roxbury, Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), This study was supported by Intergroupe Francophone du Myélome, the French Institute National du Cancer Grant POBNIMM PROG/08/10 (to H.A.L., S.M.), and National Institutes of Health Grant PO1CA155258-01 (to S.M., H.A.L., N.C.M.)., Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-École Centrale de Lyon (ECL), Université de Lyon-Université Lumière - Lyon 2 (UL2)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Université Lumière - Lyon 2 (UL2), Mines Nantes (Mines Nantes)-École Centrale de Nantes (ECN)-Ecole Polytechnique de l'Université de Nantes (EPUN), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer
Abstract

International audience; Purpose: Painful peripheral neuropathy is a frequent toxicity associated with bortezomib therapy.This study aimed to identify loci that affect susceptibility to this toxicity.Experimental Design: A genome-wide association study (GWAS) of 370,605 SNPs wasperformed to identify risk variants for developing severe bortezomib-induced peripheral neuropathy(BiPN) in 469 multiple myeloma (MM) patients who received bortezomib-dexamethasone therapyprior to autologous stem-cell in randomized clinical trials of the Intergroupe Francophone duMyelome (IFM) and findings were replicated in 114 MM patients of the HOVON-65/GMMG-HD4clinical trial.Results: A single SNP in the PKNOX1 gene was associated with BiPN in the exploratory cohort(rs2839629; OR, 1.89, 95% CI: [1.45-2.44]; P = 7.6 x 10-6) and in the replication cohort (OR, 2.04;95% CI = [1.11-3.33]; P= 8.3 x 10-3). In addition, rs2839629 is in strong linkage disequilibrium (r2= 0.87) with rs915854, located in the intergenic region between PKNOX1 and CBS . Expressionquantitative trait loci mapping showed that both rs2839629 and rs915854 genotypes impactPKNOX1 expression in nerve tissue while rs2839629 affects CBS expression in skin and blood.Conclusions: The use of GWAS in MM pharmacogenomics has identified a novel candidate geneticlocus mapping to PKNOX1 and in the immediate vicinity of CBS at 21q22.3 associated with thesevere bortezomib-induced toxicity. The proximity of these two genes involved in neurologic painwhose tissue-specific expression is modified by the two variants provides new targets for neuroprotectivestrategies.

Published
2016

35. Logic programming reveals alteration of key transcription factors in multiple myeloma

Author

Miannay, Bertrand, primary, Minvielle, Stéphane, additional, Roux, Olivier, additional, Drouin, Pierre, additional, Avet-Loiseau, Hervé, additional, Guérin-Charbonnel, Catherine, additional, Gouraud, Wilfried, additional, Attal, Michel, additional, Facon, Thierry, additional, Munshi, Nikhil C, additional, Moreau, Philippe, additional, Campion, Loïc, additional, Magrangeas, Florence, additional, and Guziolowski, Carito, additional

Published
2017
Full Text
View/download PDF

36. Additional file 6: of Gene-expression signature functional annotation of breast cancer tumours in function of age

Author

Jézéquel, Pascal, Sharif, Zein, Lasla, Hamza, Gouraud, Wilfried, Guérin-Charbonnel, Catherine, Campion, Loïc, Chrétien, Stéphane, and Campone, Mario

Abstract

GO biological process enrichment analyses of most differentially expressed genes between AG1 and AG3. Head of columns represents SAM gene lists used as ToppGene inputs. The ten first significant biological processes are displayed (cutoff p-value = 0.01). (PDF 45 kb)

Published
2015
Full Text
View/download PDF

41. Additional file 2: of Gene-expression signature functional annotation of breast cancer tumours in function of age

Author

Jézéquel, Pascal, Sharif, Zein, Lasla, Hamza, Gouraud, Wilfried, Guérin-Charbonnel, Catherine, Campion, Loïc, Chrétien, Stéphane, and Campone, Mario

Subjects
musculoskeletal diseases, congenital, hereditary, and neonatal diseases and abnormalities, animal structures, macromolecular substances, skin and connective tissue diseases
Abstract

Metastasis-free survival (MFS) and overall survival (OS) analyses. MFS: 2A1: whole cohort; 2A2: Caucasian cohort. OS: 2B1: whole cohort; 2B2: Caucasian cohort. (PDF 230 kb)

Published
2015
Full Text
View/download PDF

44. Additional file 3: of Gene-expression signature functional annotation of breast cancer tumours in function of age

Author

Jézéquel, Pascal, Sharif, Zein, Lasla, Hamza, Gouraud, Wilfried, Guérin-Charbonnel, Catherine, Campion, Loïc, Chrétien, Stéphane, and Campone, Mario

Abstract

GES scoring of breast cancer in function of age. Correlation matrices show Pearson correlation coefficients between continuous GES (red indicates a positive correlation; blue, a negative correlation) and dendrograms show mutual relationships of all signatures (scores were used for average-link hierarchical clustering using the Pearson correlation as a distance metric). 2A1: AG1, whole cohort; 2A2: AG2, whole cohort; 2A3: AG3 whole cohort; 2B1: AG1, Caucasian cohort; 2B2: AG2, Caucasian cohort; 2B3: AG3, Caucasian cohort. (PDF 1689 kb)

Published
2015
Full Text
View/download PDF

45. Can We Spare the Pancreas and Other Abdominal Organs at Risk? A Comparison of Conformal Radiotherapy, Helical Tomotherapy and Proton Beam Therapy in Pediatric Irradiation

Author

Jouglar, Emmanuel, primary, Wagner, Antoine, additional, Delpon, Grégory, additional, Campion, Loïc, additional, Meingan, Philippe, additional, Bernier, Valérie, additional, Demoor-Goldschmidt, Charlotte, additional, Mahé, Marc-André, additional, Lacornerie, Thomas, additional, and Supiot, Stéphane, additional

Published
2016
Full Text
View/download PDF

46. A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma

Author

Magrangeas, Florence, primary, Kuiper, Rowan, additional, Avet-Loiseau, Hervé, additional, Gouraud, Wilfried, additional, Guérin-Charbonnel, Catherine, additional, Ferrer, Ludovic, additional, Aussem, Alexandre, additional, Elghazel, Haytham, additional, Suhard, Jérôme, additional, Der Sakissian, Henri, additional, Attal, Michel, additional, Munshi, Nikhil C., additional, Sonneveld, Pieter, additional, Dumontet, Charles, additional, Moreau, Philippe, additional, van Duin, Mark, additional, Campion, Loïc, additional, and Minvielle, Stéphane, additional

Published
2016
Full Text
View/download PDF

50. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response

Author

Jézéquel, Pascal, primary, Loussouarn, Delphine, additional, Guérin-Charbonnel, Catherine, additional, Campion, Loïc, additional, Vanier, Antoine, additional, Gouraud, Wilfried, additional, Lasla, Hamza, additional, Guette, Catherine, additional, Valo, Isabelle, additional, Verrièle, Véronique, additional, and Campone, Mario, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results